Formerly a subsidiary of Pfizer, today Zoetis is a wholly independent public company and the global leader dedicated to the care and health of animals. The company researches, develops manufactures, and commercialises products for creatures large and small, from companion animals like dogs, cats, and horses, all the way through to livestock like beef and dairy cattle, pigs, poultry, and sheep. It has also recently added aquaculture to its portfolio.

Clint Lewis, Jr. is the Executive Vice President and President of International Operations. In this role, he oversees the management of the livestock and companion animal business across all markets outside of the US.  He initially joined the company in 1998, when it was still part of Pfizer, working in its human health division. In 2007, he transitioned into animal health.

Prior to his current appointment, Clint was the President of the US market — a region that accounts for roughly 42% of the company’s revenues and is its single largest market.

“I was also part of the executive management team that had the exciting opportunity to ‘spin out’ the animal health division from Pfizer back in 2013 via an IPO,” says Clint. “The IPO formed Zoetis and allowed us to better focus our efforts and resources to best capitalise on the macro trends driving continued growth in the animal health sector — population growth, growth in emerging economies, increased need for technology to produce food amid declining natural resources, and increased medicalisation of animals to prevent disease and improve wellbeing”.